Literature DB >> 9205080

Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes.

W E Farrell1, D J Simpson, J E Bicknell, A J Talbot, A S Bates, R N Clayton.   

Abstract

We have screened 57 cases of primary, nonfunctional, pituitary adenomas for loss of heterozygosity of markers on chromosome 9p. Using a panel of 11 microsatellite markers, we found hemizygous deletion with at least one of the markers in 18 tumors (31.5%). The frequency of loss was similar in both noninvasive (8 of 26; 31%) and invasive tumors (10 of 31; 32%), suggesting that loss on this chromosome might be an early event in pituitary tumorigenesis. Two discrete areas of loss were punctuated by a region of retention of heterozygosity between the markers D9S171 and IFNA, indicative of homozygous deletion. However, multiplex PCR analysis (MTS1 and MTS2) and the presence of a 3' untranslated region polymorphism in MTS1 suggested that neither of these tumor suppressor genes was homozygously deleted. In 6 of the 18 tumors showing LOH, sufficient DNA was also available for Southern blot analysis and, in all cases, showed retention of MTS1. Cell mixing experiments of tumor cell DNA homozygously deleted for MTS1 with DNA in which neither copy of the gene was deleted only gave rise to a signal at contamination levels greater than 30% and could discriminate homozygous and hemizygous loss. These studies support the recent findings that mechanisms other than hemi- and homozygous deletion are most likely responsible for the loss of MTS1 gene product in pituitary tumors (M. Woloschak et al., Cancer Res., 56: 2493-2486, 1996.). These data show that losses on either side of 9p21-22, both or either of which may be deleted, are involved in pituitary tumorigenesis and provide evidence for distinct suppressor gene loci, in addition to MTS1, on chromosome 9p.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9205080

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.

Authors:  P Schraml; K Struckmann; R Bednar; W Fu; T Gasser; K Wilber; J Kononen; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

Review 2.  Genetic basis of pituitary adenoma invasiveness: a review.

Authors:  A Suhardja; K Kovacs; J Rutka
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

3.  Invasive pituitary adenomas: significance of proliferation parameters.

Authors:  A P Amar; D R Hinton; M D Krieger; M H Weiss
Journal:  Pituitary       Date:  1999-08       Impact factor: 4.107

Review 4.  Molecular pathogenesis of acromegaly.

Authors:  M R Drange; S Melmed
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

Review 5.  Molecular pathology of pituitary adenomas.

Authors:  R V Lloyd
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

Review 6.  Pituitary adenomas in childhood.

Authors:  S K Singh; Rohit Aggarwal
Journal:  Indian J Pediatr       Date:  2005-07       Impact factor: 1.967

7.  Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior.

Authors:  Shyama Majumdar; Edward M Gong; Dolores Di Vizio; Jonathan Dreyfuss; David J Degraff; Martin H Hager; Peter J Park; Joaquim Bellmunt; Robert J Matusik; Jonathan E Rosenberg; Rosalyn M Adam
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

8.  Association between p16(CDKN2A) C540G polymorphism and tumor behavior in prolactinoma: A single-center study.

Authors:  Soner Cander; Mutlu Karkucak; Ozen Oz Gul; Sebnem Ozemri Sag; Tahsin Yakut; Canan Ersoy; Ercan Tuncel; Erdinc Erturk
Journal:  Biomed Rep       Date:  2014-05-19

9.  Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas.

Authors:  Atsuo Yoshino; Yoichi Katayama; Akiyoshi Ogino; Takao Watanabe; Kazunari Yachi; Takashi Ohta; Chiaki Komine; Takakazu Yokoyama; Takao Fukushima
Journal:  J Neurooncol       Date:  2007-01-11       Impact factor: 4.506

10.  Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.

Authors:  Guru Prasad Maiti; Pinaki Mondal; Nupur Mukherjee; Amlan Ghosh; Susmita Ghosh; Sanjib Dey; Jayanta Chakrabarty; Anup Roy; Jaydip Biswas; Susanta Roychoudhury; Chinmay Kumar Panda
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.